Journal: Drug metabolism reviews

Article Title: Human Cytochrome P450 Enzymes 5-51 as Targets of Drugs and Natural and Environmental Compounds: Mechanisms, Induction, and Inhibition—Toxic Effects and Benefits

doi: 10.1080/03602532.2018.1483401

Figure Lengend Snippet: P450 11B1

Article Snippet: Abiraterone, galeterone, seviteronel, orteronel a ( Yamaoka et al. 2012 ; Stein et al. 2014 ; Bird and Abbott 2016 ; Petrunak et al. 2017 ) , .

Techniques: Inhibition, Blocking Assay, Analogues

Journal: Drug metabolism reviews

Article Title: Human Cytochrome P450 Enzymes 5-51 as Targets of Drugs and Natural and Environmental Compounds: Mechanisms, Induction, and Inhibition—Toxic Effects and Benefits

doi: 10.1080/03602532.2018.1483401

Figure Lengend Snippet: P450 11B2

Article Snippet: Abiraterone, galeterone, seviteronel, orteronel a ( Yamaoka et al. 2012 ; Stein et al. 2014 ; Bird and Abbott 2016 ; Petrunak et al. 2017 ) , .

Techniques: Inhibition, Analogues

Journal: Drug metabolism reviews

Article Title: Human Cytochrome P450 Enzymes 5-51 as Targets of Drugs and Natural and Environmental Compounds: Mechanisms, Induction, and Inhibition—Toxic Effects and Benefits

doi: 10.1080/03602532.2018.1483401

Figure Lengend Snippet: P450 21A2

Article Snippet: Abiraterone, galeterone, seviteronel, orteronel a ( Yamaoka et al. 2012 ; Stein et al. 2014 ; Bird and Abbott 2016 ; Petrunak et al. 2017 ) , .

Techniques: Inhibition, Pesticides

Journal: Scientific Reports

Article Title: Drivers of AR indifferent anti-androgen resistance in prostate cancer cells

doi: 10.1038/s41598-019-50220-1

Figure Lengend Snippet: ResA and ResB cells are resistant against modern anti-androgens and androgen deprivation. ( a ) Dose response curves showing the relative proliferation rate at increasing concentrations of the AR inhibitors enzalutamide (MDV3100), RD-162, apalutamide (ARN-509), darolutamide (ODM-201), and abiraterone acetate. All measurements are normalized to vehicle treated cells and set to 100. ( b ) Relative proliferation rate in normal growth medium (containing 10 µM enzalutamide for ResA/ResB) and in androgen deprived medium (dextran-coated charcoal treated serum, DCC). The shaded areas and error bars indicate the 95% confidence interval.

Article Snippet: G.A. is on the ICR list of rewards to inventors for abiraterone and has received honoraria, consulting fees, travel support or grant support from Abbott Laboratories, Arno Therapeutics, Astellas, AstraZeneca, Bayer Healthcare Pharmaceuticals, Essa Pharmaceuticals, Genentech, Innocrin Pharma, Ipsen, Janssen, Millennium Pharmaceuticals, Novartis, Pfizer, Roche/Ventana, Sanofi-Aventis, Takeda and Veridex.

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review

doi: 10.1080/13543776.2017.1379503

Figure Lengend Snippet: Comparison of AKR1C3 inhibitors with other therapeutic agents for castration-resistant prostate cancer.

Article Snippet: No clinical benefit in terms of overall survival in Phase III clinical trial Takeda Galeterone (TOK-001) P45017A1 (lyase specific) and degrades AR-SV DHEA-SO 4 depot remains AR upregulation HSDB1 variants AKR1C3 upregulation Phase III clinical trial.

Techniques: Comparison, Expressing